Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Coexistence of EGFR mutation and ALK translocation in NSCLC: literature review and case report of response to gefitinib.

Lung cancer (Amsterdam, Netherlands) - 1 Aug 2013

Santelmo C, Ravaioli A, Barzotti E, Papi M, Poggi B, Drudi F, Mangianti M, Salvi M, Crinò L

Abstract excerpt

The coexistence of EGFR and ALK-EML4 gene mutations represents a rare event (about 1%) in patients with non small cell lung cancer (NSCLC) and the few cases described in the literature have all been treated by different methods. We present the case of a 52-year-old woman with adenocarcinoma of the lung whose tumor had this double genetic aberration. The patient was immediately treated with gefitinib because the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Adenocarcinoma of Lung

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Anaplastic Lymphoma Kinase

Share to Gefitinib

Share to Microtubule-Associated Proteins

Share to Quinazolines

Share to Receptor Protein-Tyrosine Kinases

Share to Serine Endopeptidases

Source

Identifiers

PMID: 23683537
DOI: 10.1016/j.lungcan.2013.04.009

Genes

ALK
EGFR
EML4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Coexistence of EGFR mutation and ALK translocation in NSCLC: literature review and case report of response to gefitinib.PMID 23683537Read ↗

Concomitant EML4-ALK rearrangement and EGFR mutation in non-small cell lung cancer patients: a literature review of 100 casesSemantic proximity Read ↗

A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene.Semantic proximity Read ↗

A case of lung adenocarcinoma with a concurrent EGFR mutation and ALK rearrangement: A case report and literature review.Semantic proximity Read ↗

Lung adenocarcinoma harboring concomitant EGFR mutation and EML4-ALK fusion that benefits from three kinds of tyrosine kinase inhibitors: a case report and literature review.Semantic proximity Read ↗

Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy.Semantic proximity Read ↗

[Advances in Double Mutations of EGFR and ALK Gene in Non-small Cell Lung Cancer].Semantic proximity Read ↗

EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations.Semantic proximity Read ↗

Good response to gefitinib in lung adenocarcinoma harboring coexisting EML4-ALK fusion gene and EGFR mutation.Semantic proximity Read ↗

Concomitant Presence of EGFR and ALK Fusion Gene Mutation in Adenocarcinoma of Lung: A Case Report and Review of the Literature.Semantic proximity Read ↗

Concomitant EGFR mutation and ALK rearrangement in lung adenocarcinoma is more frequent than expected: report of a case and review of the literature with demonstration of genes alteration into the same tumor cells.Semantic proximity Read ↗

Concomitant Epidermal Growth Factor Receptor Mutation and EML4-ALK Fusion in a Patient with Multifocal Lung Adenocarcinomas.Semantic proximity Read ↗

Experience with erlotinib in lung adenocarcinoma harboring a coexisting KIF5B-RET fusion gene and EGFR mutation: report of a rare case.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.